Literature DB >> 23114540

[New aspects of current therapeutic strategies in oropharyngeal carcinoma: highlights of the 2012 ASCO meeting].

M Loewenthal1, E Vitez, S Laban, A Münscher, B Güldenzoph, R Knecht, C-J Busch.   

Abstract

Beside the surgical treatment of head and neck cancer, the concept of organ and function preserving therapy of locally advanced HNSCC (head and neck squamous cell carcinoma) especially of oropharyngeal origin is becoming increasingly important. The comparison of induction chemotherapy plus chemoradiation and primary concomitant chemoradiation has recently been the subject of randomized clinical trials. New combinations of different (chemo)radiation regimens and targeted therapies are also under investigation for HNSCC. Molecular markers predicting treatment efficacy as well as new potential targets are also being evaluated in several clinical trials. The good prognosis of HPV-associated HNSCC has sparked efforts to deintensify treatment to minimize therapy-related toxicities. The impact of specific therapies is growing due to the increasing incidence of young patients with HPV-positive carcinomas.

Entities:  

Mesh:

Year:  2012        PMID: 23114540     DOI: 10.1007/s00106-012-2597-8

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  10 in total

1.  Human papillomavirus and survival of patients with oropharyngeal cancer.

Authors:  K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison
Journal:  N Engl J Med       Date:  2010-06-07       Impact factor: 91.245

2.  Prognostic implications of HPV in oropharyngeal cancer.

Authors:  Douglas R Lowy; Karl Munger
Journal:  N Engl J Med       Date:  2010-06-07       Impact factor: 91.245

3.  Foxp3+CD4+ T cell-mediated immunosuppression involves extracellular nucleotide catabolism.

Authors:  Margaret S Bynoe; Christophe Viret
Journal:  Trends Immunol       Date:  2008-02-06       Impact factor: 16.687

4.  Graft-versus-host disease: have we solved the problem?

Authors:  Sergio Giralt
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

Review 5.  FOXP3 and its role in the immune system.

Authors:  Chang H Kim
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

6.  Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial.

Authors:  Anja Lorch; Antje Kleinhans; Andrew Kramar; Christian K Kollmannsberger; Jörg T Hartmann; Carsten Bokemeyer; Oliver Rick; Jörg Beyer
Journal:  J Clin Oncol       Date:  2012-01-30       Impact factor: 44.544

Review 7.  What are regulatory T cells (Treg) regulating in cancer and why?

Authors:  Theresa L Whiteside
Journal:  Semin Cancer Biol       Date:  2012-03-28       Impact factor: 15.707

Review 8.  Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.

Authors:  Jean Bourhis; Jens Overgaard; Hélène Audry; Kian K Ang; Michele Saunders; Jacques Bernier; Jean-Claude Horiot; Aurélie Le Maître; Thomas F Pajak; Michael G Poulsen; Brian O'Sullivan; Werner Dobrowsky; Andrzej Hliniak; Krzysztof Skladowski; John H Hay; Luiz H J Pinto; Carlo Fallai; Karen K Fu; Richard Sylvester; Jean-Pierre Pignon
Journal:  Lancet       Date:  2006-09-02       Impact factor: 79.321

9.  The incidence of p53 mutations increases with progression of head and neck cancer.

Authors:  J O Boyle; J Hakim; W Koch; P van der Riet; R H Hruban; R A Roa; R Correo; Y J Eby; J M Ruppert; D Sidransky
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

10.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

Authors:  James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

  10 in total
  2 in total

1.  Epidemiology and survival of HPV-related tonsillar carcinoma.

Authors:  Georgios Psychogios; Christoph Alexiou; Abba Agaimy; Kathrin Brunner; Michael Koch; Konstantinos Mantsopoulos; Andrea Tomppert; Heinrich Iro
Journal:  Cancer Med       Date:  2014-03-10       Impact factor: 4.452

2.  Outcome and prognostic factors in T4a oropharyngeal carcinoma, including the role of HPV infection.

Authors:  Georgios Psychogios; Konstantinos Mantsopoulos; Abbas Agaimy; Kathrin Brunner; Elisabeth Mangold; Johannes Zenk; Heinrich Iro
Journal:  Biomed Res Int       Date:  2014-03-31       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.